Verrica Pharmaceuticals (VRCA) Competitors $0.69 -0.01 (-1.24%) (As of 12:03 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VRCA vs. VXRT, CABA, IFRX, NLTX, PLX, SAVA, APLT, ALGS, EDIT, and IVAShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Vaxart (VXRT), Cabaletta Bio (CABA), InflaRx (IFRX), Neoleukin Therapeutics (NLTX), Protalix BioTherapeutics (PLX), Cassava Sciences (SAVA), Applied Therapeutics (APLT), Aligos Therapeutics (ALGS), Editas Medicine (EDIT), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Vaxart Cabaletta Bio InflaRx Neoleukin Therapeutics Protalix BioTherapeutics Cassava Sciences Applied Therapeutics Aligos Therapeutics Editas Medicine Inventiva Vaxart (NASDAQ:VXRT) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, community ranking, risk, analyst recommendations, earnings, dividends and profitability. Does the media refer more to VXRT or VRCA? In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Vaxart. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 1 mentions for Vaxart. Verrica Pharmaceuticals' average media sentiment score of 0.86 beat Vaxart's score of 0.75 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxart 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in VXRT or VRCA? 18.0% of Vaxart shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 2.6% of Vaxart shares are owned by company insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, VXRT or VRCA? Verrica Pharmaceuticals has lower revenue, but higher earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$20.14M6.53-$82.46M-$0.41-1.41Verrica Pharmaceuticals$9.21M3.33-$67M-$1.83-0.37 Which has more risk and volatility, VXRT or VRCA? Vaxart has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Does the MarketBeat Community believe in VXRT or VRCA? Vaxart received 143 more outperform votes than Verrica Pharmaceuticals when rated by MarketBeat users. Likewise, 65.54% of users gave Vaxart an outperform vote while only 64.23% of users gave Verrica Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVaxartOutperform Votes31065.54% Underperform Votes16334.46% Verrica PharmaceuticalsOutperform Votes16764.23% Underperform Votes9335.77% Do analysts recommend VXRT or VRCA? Vaxart presently has a consensus price target of $3.00, indicating a potential upside of 418.58%. Verrica Pharmaceuticals has a consensus price target of $9.50, indicating a potential upside of 1,311.59%. Given Verrica Pharmaceuticals' higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Vaxart.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is VXRT or VRCA more profitable? Vaxart has a net margin of -431.61% compared to Verrica Pharmaceuticals' net margin of -625.06%. Vaxart's return on equity of -110.46% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-431.61% -110.46% -62.78% Verrica Pharmaceuticals -625.06%-591.84%-141.63% SummaryVaxart beats Verrica Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.69M$6.85B$5.15B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-0.3710.79135.4217.51Price / Sales3.33286.571,184.62142.21Price / CashN/A56.6540.4237.95Price / Book1.435.404.894.94Net Income-$67M$152.04M$118.71M$225.59M7 Day Performance-23.04%-4.19%15.74%-1.07%1 Month Performance-24.23%2.70%15.70%7.23%1 Year Performance-87.90%17.16%34.85%22.97% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals4.7488 of 5 stars$0.69-1.2%$9.50+1,274.2%-88.5%$31.52M$9.21M-0.3840VXRTVaxart2.1062 of 5 stars$0.59-0.5%$3.00+409.3%-6.7%$133.99M$20.14M-1.44109CABACabaletta Bio2.7646 of 5 stars$2.72-3.5%$26.25+865.1%-86.6%$132.95MN/A-1.3150IFRXInflaRx2.7743 of 5 stars$2.23-5.5%$8.00+258.7%+69.5%$131.31M$168,498.00-2.1960Positive NewsGap DownNLTXNeoleukin TherapeuticsN/A$13.96+1.5%N/A+82.6%$131.20MN/A-7.5690PLXProtalix BioTherapeuticsN/A$1.78-1.4%N/A+0.9%$130.69M$65.49M-13.81200News CoverageGap DownSAVACassava Sciences4.5535 of 5 stars$2.70-1.8%$111.50+4,029.6%-87.9%$129.90MN/A-1.9930News CoverageAPLTApplied Therapeutics4.5162 of 5 stars$1.11-3.5%$6.60+494.6%-62.8%$129.16M$9.99M-0.7130Gap DownALGSAligos Therapeutics4.0345 of 5 stars$35.48+4.1%$75.00+111.4%+135.7%$127.30M$6.00M-2.5690Gap UpHigh Trading VolumeEDITEditas Medicine4.4273 of 5 stars$1.53+5.9%$7.00+359.0%-86.1%$125.89M$78.12M-0.62230Analyst ForecastIVAInventiva3.2386 of 5 stars$2.32-5.3%$13.25+471.1%-45.2%$121.75M$15.62M0.00100Gap Down Related Companies and Tools Related Companies VXRT Alternatives CABA Alternatives IFRX Alternatives NLTX Alternatives PLX Alternatives SAVA Alternatives APLT Alternatives ALGS Alternatives EDIT Alternatives IVA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRCA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
